Set and Setting: Why Context Matters in Psychedelic Research

In modern psychedelic research, the pharmacological effects of a substance are understood to be only part of the equation. Equally important is the framework in which the substance is administered—a concept widely known as “set and setting.” This principle suggests that the subjective experience of a psychedelic is profoundly shaped by the individual’s internal mindset and their external physical and social environment. Recognising this has fundamentally changed how clinical trials are designed, pushing researchers to treat context as a measurable clinical variable rather than mere background noise. As jurisdictions like South Africa consider the future of substances such as psilocybin—currently listed as a Schedule 7 prohibited substance under the Medicines and Related Substances Act—understanding the role of context is essential for evaluating the scientific evidence.

The Origins of the Concept

The phrase “set and setting” was popularised in the mid-20th century, notably by the American psychologist Timothy Leary, though the underlying observations predate his work. In the 1950s and 1960s, before psychedelics were broadly prohibited internationally, early researchers studying substances like lysergic acid diethylamide (LSD) for various psychiatric conditions noticed that the outcomes were highly variable. Unlike many emerging pharmaceuticals of the era, which seemed to have predictable, dose-dependent effects, the impact of psychedelics appeared heavily influenced by the patient’s expectations and the surroundings in which the drug was administered.

Early clinicians observed that a supportive, carefully managed environment could facilitate deeply meaningful psychological experiences, whereas a sterile or hostile environment could increase the likelihood of distress. These historical observations formed the bedrock of the set and setting hypothesis, laying the groundwork for how modern science approaches psychedelic therapy today.

Defining “Set” and “Setting”

In research contexts, “set” refers to the internal mindset of the participant. This encompasses their current psychological state, their personality, their expectations of the experience, and the intentions they bring to the session. Researchers generally spend significant time preparing participants through pre-session clinical interviews to ensure their psychological “set” is stable and adequately informed.

“Setting” refers to the external environment in which the experience takes place. This includes the physical room, the sensory inputs (such as music or the use of eye masks, which are commonly used to direct attention inward), and the human element—specifically the presence of trained therapists or clinical staff who provide reassurance and a sense of safety. Together, set and setting create the container in which the altered state occurs. Contemporary researchers emphasise that the therapeutic effects observed in studies are not merely the result of neurochemistry acting in isolation, but of neurochemistry interacting with a carefully constructed psychological environment.

Why Clinical Trials Control for Context

Modern clinical trials—such as those conducted by institutions like Johns Hopkins University and Imperial College London—go to great lengths to standardise set and setting to ensure participant safety and data quality. Because psychedelics can produce intense, emotionally labile states, the environment must be meticulously managed to minimise the risk of adverse psychological reactions, such as panic or paranoia. Trials typically use comfortable, living-room-like settings rather than clinical hospital beds.

Furthermore, the presence of therapists is treated as a core component of the intervention, not just an administrative detail. The therapists act as a stabilising presence, helping participants navigate difficult emotional material that may arise during the session. Controlling for context also helps researchers isolate variables. If a participant experiences a reduction in treatment-resistant depression, scientists need to understand how much of that outcome was driven by the pharmacological action of the psilocybin versus the psychological support surrounding it. By standardising the context, researchers aim to create a reproducible therapeutic model that can be evaluated scientifically.

Implications for Drug Policy and Public Health

The recognition that set and setting are critical to outcomes poses unique challenges for drug policy and regulatory frameworks. If the therapeutic benefit of a psychedelic depends significantly on the context of administration, regulators cannot simply approve the substance in the same way they approve a standard pharmaceutical drug. The model requires the approval of an entire therapeutic protocol, including the training of therapists and the design of clinical environments.

For example, when Australia’s Therapeutic Goods Administration (TGA) rescheduled psilocybin for strictly limited medical use in 2023, the decision was tied to specific prescribing frameworks requiring authorised psychiatrists and defined clinical conditions, rather than general pharmaceutical availability. In South Africa, any future shift from the current Schedule 7 prohibition would similarly need to grapple with these contextual requirements. The South African Health Products Regulatory Authority (SAHPRA) would face the complex task of defining what constitutes a safe, legal “setting” for psychedelic therapy, ensuring that public health policy is grounded in the evidence that context, not just chemistry, drives clinical outcomes.